| Page 71 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.
  1. Home

A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients

Author(s): 
Drusbosky LM, Singh NK, Hawkins KE, Salan C, Turcotte M, Wise EA, Meacham A, Vijay V, Anderson GG, Kim CC, Radhakrishnan S, Ullal Y, Talawdekar A, Sikora H, Nair P, Khanna-Gupta A, Abbasi T, Vali S, Guha S, Farhadfar N, Murthy HS
Primary Author: 
Drusbosky LM
Journal Title: 
Blood Advances
Original Publication Date: 
Jun 2019

Patients with

Bone Marrow Disease(s): 

Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial

Author(s): 
Garcia-Manero G, Roboz G, Walsh K, Kantarjian H, Ritchie E, Kropf P, O'Connell C, Tibes R, Lunin S, Rosenblat T, Yee K, Stock W, Griffiths E, Mace J, Podoltsev N, Berdeja J, Jabbour E, Issa JJ, Hao Y, Keer HN, Azab M, Savona MR
Primary Author: 
Garcia-Manero G
Journal Title: 
The Lancet Haematology
Original Publication Date: 
Jun 2019

BACKGROUND:

Bone Marrow Disease(s): 

The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes

Author(s): 
Sekeres MA, Gore SD, Stablein DM, DiFronzo N, Abel GA, DeZern AE, Troy JD, Rollison DE, Thomas JW, Waclawiw MA, Liu JJ, Al Baghdadi T, Walter MJ, Bejar R, Gorak EJ, Starczynowski DT, Foran JM, Cerhan JR, Moscinski LC
Primary Author: 
Sekeres MA
Journal Title: 
Leukemia & Lymphoma
Original Publication Date: 
May 2019

Bone Marrow Disease(s): 

Management of myelodysplastic syndromes after failure of response to hypomethylating agents

Author(s): 
Gil-Perez A, Montalban-Bravo G
Primary Author: 
Gil-Perez A
Journal Title: 
Therapeutic Advances in Hematology
Original Publication Date: 
May 2019

Hypomethylating agents (HMAs) are the standard of care for patients with myelodysplastic syndrome (MDS). However, only around 50% of patients respond to these agents, and responses tend to be transient, with loss of response frequently happening within 2 years and being associated with very poor prognosis and limited therapeutic options. Identification of patients who will respond to HMAs is challenging. Mechanisms underlying resistance to HMAs are not clear yet.

Bone Marrow Disease(s): 

The case for upfront HLA-matched unrelated donor HCT as a curative option for adult acquired severe aplastic anemia: Upfront MUD HCT for adult severe aplastic anemia

Author(s): 
Marsh JC, Risitano AM, Mufti GJ
Primary Author: 
Marsh JC
Journal Title: 
Biology of Blood and Marrow Transplantation: Journal of the American Society of Blood and Marrow Transplantation
Original Publication Date: 
May 2019

Improved success of HLA-matched unrelated donor (MUD) hematopoietic stem cell transplantation (HCT) for severe

Bone Marrow Disease(s): 

Immunosuppressive therapy for pediatric aplastic anemia: a North American Pediatric Aplastic Anemia Consortium study

Author(s): 
Rogers ZR, Nakano TA, Olson TS, Bertuch AA, Wang W, Gillio A, Coates TD, Chawla A, Castillo P, Kurre P, Gamper C, Bennett CM, Joshi S, Geddis AE, Boklan J, Nalepa G, Rothman JA, Huang JN, Kupfer GM, Cada M, Glader B, Walkovich KJ, Thompson AA, Hanna R
Primary Author: 
Rogers ZR
Journal Title: 
Haematologica
Original Publication Date: 
Apr 2019

Quality of response to immunosuppressive therapy and long-term outcomes for pediatric severe

Bone Marrow Disease(s): 

Eltrombopag for refractory severe aplastic anemia: dosing, duration, long term outcomes and clonal evolution

Author(s): 
Winkler T, Fan X, Cooper J, Desmond R, Young DJ, Townsley DM, Scheinberg P, Grasmeder S, Larochelle A, Desierto M, Valdez J, Lotter J, Wu C, Shalhoub RN, Calvo KR, Young NS, Dunbar CE
Primary Author: 
Winkler T
Journal Title: 
Blood
Original Publication Date: 
Apr 2019

Eltrombopag received FDA approval for the treatment of refractory severe

Bone Marrow Disease(s):